Reimbursement Is Neurotech's Biggest Risk with Juan-Pablo Mas

In this episode, your host, Liz Moyles, is joined by Juan-Pablo Mas, Managing Director at Action Potential VC to talk about investing at the frontier of neurotech and bioelectronic medicine, and why reimbursement, not technology, is so often the make-or-break risk.Juan-Pablo traces his path from electrical engineering and a formative stint in Medtronic's cardiovascular division, through Stanford Biodesign and his first venture roles at Morgenthaler and Lightstone, to a decade investing in the brain and nervous system at Action Potential and now the Synapse Fund.He explains what he looks for in founders, why "herd mentality" in venture is where the real opportunity hides, how AI and signal processing are reshaping neurotech, and where he sees the healthcare system heading as clinical resources become more abundant.Key Topics:Juan-Pablo's route from engineering and Medtronic to venture and the Synapse FundInvesting in neuromodulation, bioelectronic medicine and the wider neurotech marketHow AI, signal processing and machine learning are accelerating the fieldWhat separates fundable founders from the restWhy reimbursement is the single biggest risk in neurotech todayRelated Insights:The "thirsty learner" founder mindset saying "I don't know, but I'll find out"Why a unique, against-the-grain take is where returns are madeChoosing investors and boards who actually understand the business technicallyThe shift toward preventative health as an investable categoryDesigning healthcare for abundance agentic tools, BCI and what comes nextCore Challenges:Reimbursement and coverage decisions not the technology are often the hardest, riskiest part of bringing a neurotech to market. Agencies can default to denial, and a single coverage setback can hit a company exactly when its burn is highest.Founders need a credible reimbursement and commercialisation strategy from day one, and a board that genuinely understands the business otherwise they risk setting up failure at later rounds without realising it.🎧 Tune in now to hear why the brain is medtech's last great frontier and what it really takes to fund and build there.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠